GAMMA Investing LLC Increases Stake in Smith & Nephew plc (NYSE:SNN)

GAMMA Investing LLC boosted its position in Smith & Nephew plc (NYSE:SNN) by 160.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 2,257 shares of the medical equipment provider’s stock after acquiring an additional 1,389 shares during the period. GAMMA Investing LLC’s holdings in Smith & Nephew were worth $70,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mather Group LLC. lifted its stake in shares of Smith & Nephew by 9,735.3% during the 2nd quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 1,655 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Smith & Nephew by 1,894.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 1,648 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Smith & Nephew by 92.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,454 shares of the medical equipment provider’s stock worth $61,000 after acquiring an additional 1,179 shares during the period. Headlands Technologies LLC grew its position in shares of Smith & Nephew by 225.0% in the first quarter. Headlands Technologies LLC now owns 3,851 shares of the medical equipment provider’s stock valued at $98,000 after purchasing an additional 2,666 shares in the last quarter. Finally, Opal Wealth Advisors LLC bought a new stake in shares of Smith & Nephew during the 2nd quarter valued at $101,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew Trading Down 0.5 %

NYSE:SNN opened at $28.49 on Wednesday. Smith & Nephew plc has a 52-week low of $21.52 and a 52-week high of $31.72. The stock has a fifty day moving average of $30.41 and a 200 day moving average of $27.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Analysts Set New Price Targets

Several research analysts have commented on the company. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Smith & Nephew in a research report on Wednesday, July 24th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.